Novartis reports 2014 Q1 sales, profit growth

Novartis reported a 1% increase in net sales to $14 billion in the first quarter of 2014, according to a press release.

“Novartis delivered a solid quarter, with all divisions contributing to growth. We made progress in innovation, including [European Union] and U.S. approval of Xolair in chronic spontaneous urticaria and significant milestones for Bexsero,” Joseph Jimenez, CEO of Novartis, said in the release.

Alcon net sales were reported at $2.6 billion, marking a 3% increase from 2013. Surgical performance increased 6%, driven by equipment growth, and vision care increased 4% from sales in contact lenses, the release said.

Alcon’s operating income was $380 million, an 8% decrease from 2013, and core operating income was reported at $925 million, a 2% decrease from 2013.

Novartis reported a 1% increase in net sales to $14 billion in the first quarter of 2014, according to a press release.

“Novartis delivered a solid quarter, with all divisions contributing to growth. We made progress in innovation, including [European Union] and U.S. approval of Xolair in chronic spontaneous urticaria and significant milestones for Bexsero,” Joseph Jimenez, CEO of Novartis, said in the release.

Alcon net sales were reported at $2.6 billion, marking a 3% increase from 2013. Surgical performance increased 6%, driven by equipment growth, and vision care increased 4% from sales in contact lenses, the release said.

Alcon’s operating income was $380 million, an 8% decrease from 2013, and core operating income was reported at $925 million, a 2% decrease from 2013.